Replimune cries foul on regulatory flexibility. But many Americans want a stricter FDA

BioSpace

After Replimune’s advanced melanoma drug was rejected for a second time, CEO Sushil Patel slammed the FDA for failing to exercise regulatory flexibility, while other experts bemoaned the agency’s lack

RegulatoryRead full story